Details of Drug-Drug Interaction
| Drug General Information (ID: DDIJUP4S8K) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Acetylsalicylic acid | Drug Info | Dalteparin | Drug Info | |||||
| Drug Type | Small molecule | Small molecule | |||||||
| Therapeutic Class | Analgesics | Anticoagulants | |||||||
| Structure | |||||||||
| Mechanism of Acetylsalicylic acid-Dalteparin Interaction (Severity Level: Major) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Increased risk of bleeding Click to Show/Hide Mechanism Graph | |||||||||
![]() |
|||||||||
| Drug Name | Acetylsalicylic acid | Dalteparin | |||||||
| Mechanism |
Risk of bleeding Antiplatelet |
Risk of bleeding Anticoagulant |
|||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Bleeding | ||||||||
| Factor Description | Patients may be at risk for bleeding when the outcome of a disease or disease treatment confounds the standard mechanisms for maintaining hemostasis. Signs or symptoms of abnormal bleeding include: bleeding that takes a long time to stop (including nosebleeds, bleeding gums, bleeding from cuts and abrasions, and menstrual bleeding); severe unexplained bruising, or bruising that becomes larger; blood in the urine or stool, etc. | ||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | Products containing NSAIDs, especially if given chronically and in high dosages, should preferably be avoided in patients receiving LMWHs or heparinoids. Close clinical and laboratory observation for bleeding complications is recommended if concurrent therapy is necessary. In patients undergoing neuraxial intervention, coadministration of these agents should be approached with caution and only after thorough assessment of risks and benefits. | ||||||||

